The CARAMBA-1 study (NCT04499339) is evaluating the safety and efficacy of autologous CS1-targeted CAR-T cells in patients with late-stage MM for whom conventional therapies have been exhausted. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.